Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of APX3330 in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1 Study of APX3330 in Patients With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APX 3330 (Primary)
  • Indications Bladder cancer; Colon cancer; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Liver cancer; Malignant melanoma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Rectal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Apexian Pharmaceuticals
  • Most Recent Events

    • 01 Nov 2021 According to an Ocuphire Pharma media release, data from this trial will be presented at the upcoming American Academy of Ophthalmology (AAO) 2021 annual meeting.
    • 01 Oct 2021 According to an Ocuphire Pharma media release, data from this trial was accepted for podium presentation and discussion at the 39th Annual Meeting of the American Society of Retina Specialists (ASRS).
    • 03 Sep 2020 Status changed from recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top